Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News X4 Pharmaceuticals Inc XFOR

Healthcare Biotechnology
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections... see more

Current News (NDAQ:XFOR)

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

GlobeNewswire 10 days ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 11 days ago

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

GlobeNewswire February 27, 2026

X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026

GlobeNewswire February 3, 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 2, 2026

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

GlobeNewswire November 5, 2025

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 5, 2025

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

GlobeNewswire October 27, 2025

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

GlobeNewswire October 24, 2025
View More News ››

Opinion & Analysis (NDAQ:XFOR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:XFOR)

Using technical analysis for this stock.

After making a head and shoulders formation recently this stock is going up and it is looking really good for shareholders here today...
coolfooldumbguy - August 13, 2025
View more Bullboard ››

FPX Nickel Corp.

FPX Nickel Corp.

FPX Nickel Corp., a junior nickel mining company, engages in the acquisition, exploration, and development of mineral ...
View More »

Podcasts